Logo image of PACS

PACS GROUP INC (PACS) Stock Fundamental Analysis

USA - NYSE:PACS - US69380Q1076 - Common Stock

26.14 USD
+9.31 (+55.32%)
Last: 11/20/2025, 8:14:57 PM
26.2 USD
+0.06 (+0.23%)
After Hours: 11/20/2025, 8:14:57 PM
Fundamental Rating

3

Overall PACS gets a fundamental rating of 3 out of 10. We evaluated PACS against 100 industry peers in the Health Care Providers & Services industry. PACS has a bad profitability rating. Also its financial health evaluation is rather negative. PACS has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

PACS had positive earnings in the past year.
PACS Yearly Net Income VS EBIT VS OCF VS FCFPACS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 0 50M -50M 100M 150M 200M

1.2 Ratios

PACS has a Return On Assets of 2.90%. This is in the better half of the industry: PACS outperforms 63.00% of its industry peers.
PACS's Return On Equity of 19.73% is amongst the best of the industry. PACS outperforms 88.00% of its industry peers.
With a Return On Invested Capital value of 4.38%, PACS perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
Industry RankSector Rank
ROA 2.9%
ROE 19.73%
ROIC 4.38%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PACS Yearly ROA, ROE, ROICPACS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 50 100 150 200

1.3 Margins

PACS's Profit Margin of 3.63% is fine compared to the rest of the industry. PACS outperforms 72.00% of its industry peers.
PACS has a better Operating Margin (6.68%) than 67.00% of its industry peers.
The Gross Margin of PACS (21.33%) is comparable to the rest of the industry.
Industry RankSector Rank
OM 6.68%
PM (TTM) 3.63%
GM 21.33%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PACS Yearly Profit, Operating, Gross MarginsPACS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 5 10 15 20

More info and screens

3

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so PACS is destroying value.
Compared to 1 year ago, PACS has about the same amount of shares outstanding.
PACS has a worse debt/assets ratio than last year.
PACS Yearly Shares OutstandingPACS Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 50M 100M
PACS Yearly Total Debt VS Total AssetsPACS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 1B 2B 3B

2.2 Solvency

PACS has an Altman-Z score of 1.58. This is a bad value and indicates that PACS is not financially healthy and even has some risk of bankruptcy.
PACS's Altman-Z score of 1.58 is on the low side compared to the rest of the industry. PACS is outperformed by 62.00% of its industry peers.
PACS has a Debt/Equity ratio of 0.90. This is a neutral value indicating PACS is somewhat dependend on debt financing.
PACS's Debt to Equity ratio of 0.90 is in line compared to the rest of the industry. PACS outperforms 42.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.9
Debt/FCF N/A
Altman-Z 1.58
ROIC/WACC0.48
WACC9.05%
PACS Yearly LT Debt VS Equity VS FCFPACS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 1.71 indicates that PACS should not have too much problems paying its short term obligations.
PACS has a Current ratio of 1.71. This is in the better half of the industry: PACS outperforms 64.00% of its industry peers.
A Quick Ratio of 1.71 indicates that PACS should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.71, PACS is in the better half of the industry, outperforming 69.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.71
Quick Ratio 1.71
PACS Yearly Current Assets VS Current LiabilitesPACS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

PACS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -25.00%.
Looking at the last year, PACS shows a very strong growth in Revenue. The Revenue has grown by 28.47%.
EPS 1Y (TTM)-25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-144.3%
Revenue 1Y (TTM)28.47%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%29.08%

3.2 Future

Based on estimates for the next years, PACS will show a very strong growth in Earnings Per Share. The EPS will grow by 37.45% on average per year.
Based on estimates for the next years, PACS will show a quite strong growth in Revenue. The Revenue will grow by 18.92% on average per year.
EPS Next Y92.3%
EPS Next 2Y46.69%
EPS Next 3Y37.45%
EPS Next 5YN/A
Revenue Next Year28.62%
Revenue Next 2Y22.64%
Revenue Next 3Y18.92%
Revenue Next 5YN/A

3.3 Evolution

PACS Yearly Revenue VS EstimatesPACS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 1B 2B 3B 4B 5B
PACS Yearly EPS VS EstimatesPACS Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 0.5 1 1.5

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 34.39 indicates a quite expensive valuation of PACS.
Based on the Price/Earnings ratio, PACS is valued a bit cheaper than the industry average as 64.00% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of PACS to the average of the S&P500 Index (25.07), we can say PACS is valued slightly more expensively.
PACS is valuated correctly with a Price/Forward Earnings ratio of 15.90.
Compared to the rest of the industry, the Price/Forward Earnings ratio of PACS indicates a rather cheap valuation: PACS is cheaper than 88.00% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 34.08, PACS is valued rather cheaply.
Industry RankSector Rank
PE 34.39
Fwd PE 15.9
PACS Price Earnings VS Forward Price EarningsPACS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, PACS is valued a bit cheaper than 62.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 13.15
PACS Per share dataPACS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20

4.3 Compensation for Growth

PACS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PACS's earnings are expected to grow with 37.45% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.37
PEG (5Y)N/A
EPS Next 2Y46.69%
EPS Next 3Y37.45%

More info and screens

0

5. Dividend

5.1 Amount

PACS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PACS GROUP INC

NYSE:PACS (11/20/2025, 8:14:57 PM)

After market: 26.2 +0.06 (+0.23%)

26.14

+9.31 (+55.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)N/A N/A
Inst Owners29.06%
Inst Owner Change-3.17%
Ins Owners71.8%
Ins Owner Change0%
Market Cap4.06B
Revenue(TTM)3.11B
Net Income(TTM)112.87M
Analysts83.64
Price Target27.88 (6.66%)
Short Float %7.21%
Short Ratio2.35
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)40.28%
Min EPS beat(2)24.18%
Max EPS beat(2)56.37%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)3.83%
Min Revenue beat(2)2.62%
Max Revenue beat(2)5.03%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-17.17%
PT rev (3m)-20.54%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 34.39
Fwd PE 15.9
P/S 1.3
P/FCF N/A
P/OCF N/A
P/B 7.09
P/tB 8
EV/EBITDA 13.15
EPS(TTM)0.76
EY2.91%
EPS(NY)1.64
Fwd EY6.29%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS20.05
BVpS3.69
TBVpS3.27
PEG (NY)0.37
PEG (5Y)N/A
Graham Number7.94
Profitability
Industry RankSector Rank
ROA 2.9%
ROE 19.73%
ROCE 6.06%
ROIC 4.38%
ROICexc 4.47%
ROICexgc 4.56%
OM 6.68%
PM (TTM) 3.63%
GM 21.33%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.8
Health
Industry RankSector Rank
Debt/Equity 0.9
Debt/FCF N/A
Debt/EBITDA 2.21
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.71
Quick Ratio 1.71
Altman-Z 1.58
F-ScoreN/A
WACC9.05%
ROIC/WACC0.48
Cap/Depr(3y)671.95%
Cap/Depr(5y)N/A
Cap/Sales(3y)4.35%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-144.3%
EPS Next Y92.3%
EPS Next 2Y46.69%
EPS Next 3Y37.45%
EPS Next 5YN/A
Revenue 1Y (TTM)28.47%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%29.08%
Revenue Next Year28.62%
Revenue Next 2Y22.64%
Revenue Next 3Y18.92%
Revenue Next 5YN/A
EBIT growth 1Y-9.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year86.13%
EBIT Next 3Y32.1%
EBIT Next 5YN/A
FCF growth 1Y-74.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.22%
OCF growth 3YN/A
OCF growth 5YN/A

PACS GROUP INC / PACS FAQ

What is the fundamental rating for PACS stock?

ChartMill assigns a fundamental rating of 3 / 10 to PACS.


What is the valuation status for PACS stock?

ChartMill assigns a valuation rating of 5 / 10 to PACS GROUP INC (PACS). This can be considered as Fairly Valued.


What is the profitability of PACS stock?

PACS GROUP INC (PACS) has a profitability rating of 3 / 10.


What are the PE and PB ratios of PACS GROUP INC (PACS) stock?

The Price/Earnings (PE) ratio for PACS GROUP INC (PACS) is 34.39 and the Price/Book (PB) ratio is 7.09.


How financially healthy is PACS GROUP INC?

The financial health rating of PACS GROUP INC (PACS) is 3 / 10.